801 related articles for article (PubMed ID: 26490736)
21. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
22. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
23. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
[TBL] [Abstract][Full Text] [Related]
24. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
26. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
27. CHFR hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Gao L; Liu F; Zhang H; Sun J; Ma Y
Genes Chromosomes Cancer; 2016 Feb; 55(2):158-68. PubMed ID: 26542416
[TBL] [Abstract][Full Text] [Related]
28. [Alteration of methylation status of death-associated protein kinase (dapk) gene promoter in patients with acute myeloid leukemia].
Qian J; Yao DM; Lin J; Chen Q; Li Y; Ji RB; Yang J; Qian Z; Xiao GF; Wang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1390-4. PubMed ID: 21176336
[TBL] [Abstract][Full Text] [Related]
29. [Expression of TFPI-2 gene and its promoter methylation in acute myeloid leukemia].
Shao LL; Fan J; Wang R; Feng LL; Zhen CQ; Sui XH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):920-6. PubMed ID: 25130804
[TBL] [Abstract][Full Text] [Related]
30. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.
Qu X; Davison J; Du L; Storer B; Stirewalt DL; Heimfeld S; Estey E; Appelbaum FR; Fang M
Epigenetics; 2015; 10(6):526-35. PubMed ID: 25996682
[TBL] [Abstract][Full Text] [Related]
31. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
32. [The expression and clinical significance of miR-203 in pediatric acute leukemia].
Wang N; Pan J; Cao L; Lu J; Xiao PF; Zhao WL; Hu SY; Chai YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):777-81. PubMed ID: 24103876
[TBL] [Abstract][Full Text] [Related]
33. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.
Jost E; Schmid J; Wilop S; Schubert C; Suzuki H; Herman JG; Osieka R; Galm O
Br J Haematol; 2008 Sep; 142(5):745-53. PubMed ID: 18537968
[TBL] [Abstract][Full Text] [Related]
35. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
Zhang YY; Yao DM; Zhu XW; Zhou JD; Ma JC; Yang J; Wen XM; Guo H; Lin J; Qian J
Leuk Res; 2015 Oct; 39(10):1041-7. PubMed ID: 26242829
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
Galm O; Wilop S; Lüders C; Jost E; Gehbauer G; Herman JG; Osieka R
Ann Hematol; 2005 Dec; 84 Suppl 1():39-46. PubMed ID: 16231140
[TBL] [Abstract][Full Text] [Related]
37. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
[TBL] [Abstract][Full Text] [Related]
38. Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia.
Jost E; do O N; Wilop S; Herman JG; Osieka R; Galm O
Leuk Res; 2009 Mar; 33(3):443-9. PubMed ID: 18757096
[TBL] [Abstract][Full Text] [Related]
39. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
40. [Studies on gene expression and the 5' CpG islands methylation status of E-cadherin in acute myeloid leukemia].
Gao F; Li Y; Liu W; Lu XL; Li X; Wang PP; Liu YP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):25-7. PubMed ID: 16732935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]